Publications by authors named "Droitcourt C"
Background: Patients with atopic dermatitis (AD) may discontinue dupilumab owing to dupilumab-induced ocular adverse events (DOAEs) or dupilumab-induced facial redness (DFR).
Objective: To evaluate DOAE and DFR outcomes after switching to tralokinumab or Janus kinase inhibitor (JAKi).
Methods: This retrospective study included 106 patients discontinuing dupilumab because of DOAEs and/or DFR.
Mycosis fungoides (MF) and Sezary syndrome (SS) are common entities among primary cutaneous lymphomas. Large cell transformation is challenging for diagnosis and therapy. Molecular mechanisms by which these lymphomas undergo this transformation are poorly defined.
View Article and Find Full Text PDFAtopic dermatitis and vitamin D supplementation: The end of the story?
J Eur Acad Dermatol Venereol
September 2024
Article Synopsis
- The study explores the effectiveness of one-on-one, nurse-led therapeutic patient education (TPE) for children with moderate-to-severe atopic dermatitis (AD), pitting it against standard care alone.
- A total of 176 children participated, but by week 24, there was no significant difference in disease control (measured by the SCORAD index) between the two groups.
- The only notable improvement from the TPE was a reduction in fear of using topical steroids, although the intervention group displayed consistently lower disease severity throughout the study.
Article Synopsis
- Systemic lupus erythematosus (SLE) often affects the lungs, and the study investigates the significance of diffusing capacity of the lungs for carbon monoxide (DLCO) in evaluating lung function in SLE patients.
- A retrospective analysis of 232 SLE patients revealed that 66.4% experienced DLCO alterations, which were linked to factors such as smoking history, interstitial lung disease, and renal or neurological involvement.
- The findings indicate that DLCO alterations may serve as a prognostic indicator for severe disease outcomes, including ICU admissions and increased mortality, suggesting a connection to SLE-related vascular damage.
Omalizumab Drug Survival in Chronic Urticaria: A Retrospective Multicentric French Study.
J Allergy Clin Immunol Pract
December 2023
Background: Omalizumab (OMA) dramatically improves disease control and quality of life in patients with chronic urticaria (CU).
Objective: We aimed to evaluate the discontinuation patterns of OMA and their determinants in a cohort of French patients with CU.
Methods: We conducted a retrospective multicenter study in 9 French tertiary referral hospitals.
Purpose: Intramuscular capillary-type hemangiomas (ICTHs) are rare entities, belonging to the group of intramuscular "hemangiomas." The diagnosis remains challenging. We aimed to assess the diagnostic criteria, treatments and outcomes of ICTHs.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to analyze the risk of major adverse cardiovascular events (MACE) in patients with atopic dermatitis (AD) who are treated with Janus kinase inhibitors (JAKi), as previous data linked JAKi use to cardiovascular issues in other inflammatory diseases.* -
- A systematic review and meta-analysis were conducted, examining multiple databases for relevant studies, which included cohorts of patients aged 12 and older, revealing a total of 9,309 in the 'controlled-period' cohort and 9,118 in the 'all-JAKi' cohort.* -
- The findings indicated that among the 23 selected studies, patients had been treated with various JAKi drugs, including baricitinib and upad
Background: The factors associated with early relapse of infantile haemangioma (IH) after a first course of treatment with oral propranolol for at least six months (initiated after the marketing authorization had been granted) have not previously been investigated.
Objectives: To identify factors associated with the risk of early relapse in children with IH treated with oral propranolol according to the current prescribing guidelines.
Methods: We performed a multicentre, retrospective, case-control study, using the Ouest Data Hub database.
Introduction: Atopic dermatitis (AD) is a highly prevalent, chronic, inflammatory skin disease. Several orally administered Janus kinase inhibitors (JAKis, including baricitinib, upadacitinib and abrocitinib) have received a marketing authorisation for AD.Clinical trials in rheumatoid arthritis (RA) have flagged up a potential risk of JAKi-induced venous thromboembolic events (VTEs).
View Article and Find Full Text PDFBackground: Dupilumab is the first biotherapy available for the treatment of moderate-to-severe childhood atopic dermatitis (AD).
Objective: The aim of this study was to evaluate the effectiveness and safety of dupilumab in daily practice.
Methods: Patients aged 6-11, who had received a first dose of dupilumab, were included in this multicentre retrospective cohort study.
Article Synopsis
- Biological therapies are effective for treating severe psoriasis in children under 12, but this age group is often not included in clinical trials.
- The 'BiPe Jr' study analyzed data from 82 children in France and Italy who received biological treatments, showcasing significant improvement in psoriasis severity and treatment duration for drugs like adalimumab and ustekinumab.
- Although 52 children stopped their treatments mostly due to ineffectiveness and remission, the study pointed out safety concerns with reports of serious adverse events, including severe infections.
Coloboma, congenital heart disease, ichthyosiform dermatosis, mental retardation, and ear anomalies (CHIME) syndrome is a very rare autosomal recessive neuroectodermal disorder related to PIGL gene mutations. Here, we report a patient who showed an initial delay in psychomotor development and skin abnormalities consistent with CHIME syndrome but with atypical clinical features and laboratory findings. In line with our clinical suspicion, the c.
View Article and Find Full Text PDFBackground: Congenital nail matrix nevi (NMN) are difficult to diagnose because they feature clinical characteristics suggestive of adult subungual melanoma. Nail matrix biopsy is difficult to perform, especially in children.
Objective: To describe the initial clinical and dermatoscopic features of NMN appearing at birth (congenital) or after birth but before the age of 5 years (congenital-type).
Article Synopsis
- The study aimed to analyze the clinical practice and safety of switching biologics among pediatric psoriasis patients in the BiPe cohort, which included 134 patients.
- Out of the patients, 29 switched biologics mainly due to loss of efficacy, with most transitions occurring from etanercept to adalimumab or ustekinumab.
- The research found no significant differences in drug survival rates based on whether the biologics were used as first-line or second-line treatments, indicating a need for more data to guide switching in clinical practice.